You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 71 No. 1, January 1964 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (36)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Toxoplasmic Retinochoroiditis: A Double Blind Therapeutic Study

THOMAS E. ACERS, MD

Arch Ophthalmol. 1964;71(1):58-62.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Introduction

The treatment of toxoplasmic retinochoroiditis has been the subject of numerous investigations over the past ten years. Therapeutic regimes seem to fall into four general groups: (1) watchful waiting, (2) corticosteroids, (3) pyrimethamine (Daraprim) and sulfonamides, with or without corticosteroids, and (4) antimicrobial agents such as spiramycin, chlortetracycline (Aureomycin), chloramphenicol (Chloromycetin), etc. Since the earliest studies of Sabin and Warner25 in 1942, in which the therapeutic effectiveness of sulfonamides in toxoplasmosis of mice and rabbits was demonstrated, extensive investigations have been made to find a more specific therapeutic agent effective against this organism.

In 1952, Eyles and Coleman6 initiated the first systematic survey of a number of compounds for antitoxoplasmic activity. These included the broad spectrum antibiotics, such as chloramphenicol, tetracyclines, neomycin, etc. The antitoxoplasmic activity of these compounds was slight and then only when used in extremely high doses.

In March of 1952, these authors reported . . . [Full Text PDF of this Article]


Author Affiliations

Lawton, Okla

From the Wilmer Ophthalmological Institute of The Johns Hopkins Hospital, Baltimore 5, Md.


Footnotes

Submitted for publication June 27, 1963.

This study was supported by the Training Grant, No. 2B-5217, from the National Institute of Neurological Diseases and Blindness, US Public Health Service.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1964 American Medical Association. All Rights Reserved.